Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors

Annals of Surgery

Volumn 267, Issue 6, 2018, Pages 1161-1168

  Locke, Jayme E ^a   Sawinski, Deirdre ^b   Reed, Rhiannon D ^a   Shelton, Brittany ^a   Maclennan, Paul A ^a   Kumar, Vineeta ^a   Mehta, Shikha ^a   Mannon, Roslyn B ^a   Gaston, Robert ^a   Julian, Bruce A ^a   Carr, John J ^c   Terry, James G ^c   Kilgore, Meredith ^d   Massie, Allan B ^e   Segev, Dorry L ^e   Lewis, Cora E ^f  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

APOL1; CARDIA; chronic kidney disease; living kidney donation; risk prediction

Indexed keywords

APOLIPOPROTEIN L1; APOL1 PROTEIN, HUMAN;

ACCURACY; ADULT; AFRICAN AMERICAN; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONFERENCE PAPER; CONTRAINDICATION; CONTROLLED STUDY; DONOR SELECTION; ESTIMATED GLOMERULAR FILTRATION RATE; ETHNICITY; EUROPEAN AMERICAN; FAMILY HISTORY; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HUMAN; KIDNEY DONOR; LIVING DONOR; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; YOUNG ADULT; ADOLESCENT; CAUCASIAN; GENETICS; GENOTYPE; KIDNEY TRANSPLANTATION; PROCEDURES;

ADOLESCENT; ADULT; AFRICAN AMERICANS; APOLIPOPROTEIN L1; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; YOUNG ADULT;

EID: 85012154652     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000002174     Document Type: Conference Paper

References (50)

1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2012 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration; 2014.
2. United States Renal Data System. Annual Data Report: Atlas of Chronic Kidney Disease and End-stage Renal Disease. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013.
3. Segev DL, Muzaale AD, Caffo BS, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA. 2010;303: 959-966.
4. Muzaale AD, Massie AB, Wang MC, et al. Risk of end-stage renal disease following live kidney donation. JAMA. 2014;311:579-586.
5. Tarver-Carr ME, Powe NR, Eberhardt MS, et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol. 2002;13:2363-2370.
6. Grams ME, Sang Y, Levey AS, et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med. 2016;374:411-421.
7. Khalili H, Sull A, Sarin S, et al. Developmental origins for kidney disease due to SHROOM3 deficiency. J Am Soc Nephrol. 2016;27:2965-2973.
8. Reznichenko A, Boger CA, Snieder H, et al. UMOD as a susceptibility gene for end-stage renal disease. BMC Med Genet. 2012;13:78.
9. Friedman DJ, Pollak MR. Genetics of kidney failure and the evolving story of APOL1. J Clin Invest. 2011;121:3367-3374.
10. Friedman DJ, Kozlitina J, Genovese G, et al. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol. 2011;22:2098-2105.
11. Foster MC, Coresh J, Fornage M, et al. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol. 2013;24:1484-1491.
12. Peralta CA, Bibbins-Domingo K, Vittinghoff E, et al. APOL1 genotype and race differences in incident albuminuria and renal function decline. J Am Soc Nephrol. 2016;27:887-893.
13. Grams ME, Rebholz CM, Chen Y, et al. Race, APOL1 risk, and eGFR decline in the general population. J Am Soc Nephrol. 2016;27:2842-2850.
14. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329:841-845.
15. Riella LV, Sheridan AM. Testing for high-risk APOL1 alleles in potential living kidney donors. Am J Kidney Dis. 2015;66:396-401.
16. Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988;41:1105-1116.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
18. Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006;52:5-18.
19. Muntner P, Newsome B, Kramer H, et al. Racial differences in the incidence of chronic kidney disease. Clin J Am Soc Nephrol. 2012;7:101-107.
20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
21. Hastings C, Mosteller F, Tukey JW, et al. Low moments for small samples: a comparative study of order statistics. Ann Math Stat. 1947;18:413-426.
22. Evaluation of the Living Kidney Donor-a Consensus Document from the AST/ASTS/NATCO/UNOS Joint Societies Work Group. Paper presented at: Joint Societies Work Group of the Joint Societies Steering Committee2010; Rockville, M.D.
23. Krohn AG, Ogden DA, Holmes JH. Renal function in 29 healthy adults before and after nephrectomy. JAMA. 1966;196:322-324.
24. Moody WE, Chue CD, Inston NG, et al. Understanding the effects of chronic kidney disease on cardiovascular risk: are there lessons to be learnt from healthy kidney donors J Hum Hypertens. 2012;26:141-148.
25. Chang A, Van Horn L, Jacobs DR Jr, et al. Lifestyle-related factors, obesity, and incident microalbuminuria: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Kidney Dis. 2013;62:267-275.
26. Bansal N, Vittinghoff E, Peralta CA, et al. Estimated kidney function based on serum cystatin C and risk of subsequent coronary artery calcium in young and middle-aged adults with preserved kidney function: results from the CARDIA study. Am J Epidemiol. 2013;178:410-417.
27. National Chronic Kidney Disease Fact Sheet. 2014. Available at: http:// www.cdc.gov/diabetes/pubs/factsheets/kidney.htm#2. Accessed January 30, 2014.
28. Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. Jama. 2004;291:844-850.
29. Wang Y, Chen X, Song Y, et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73: 19-33.
30. Haroun MK, Jaar BG, Hoffman SC, et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women inWashington County, Maryland. J Am Soc Nephrol. 2003;14:2934-2941.
31. Shankar A, Klein R, Klein BEK. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol. 2006;164:263-271.
32. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12.
33. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167-174.
34. Schaeffner ES, Kurth T, Bowman TS, et al. Blood pressure measures and risk of chronic kidney disease in men. Nephrol Dial Transplant. 2008;23:1246-1251.
35. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med. 2004;23:1631-1660.
36. Steyerberg EW, Harrell FE Jr, Borsboom GJ, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54:774-781.
37. Harrell F. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
38. Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika. 1990;77:147-160.
39. Hosmer DW, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time-to-Event Data. Hoboken, NJ: Wiley-Interscience; 2008.
40. Gronnesby JK, Borgan O. A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal. 1996;2:315-328.
41. Mjoen G, Hallan S, Hartmann A, et al. Long-term risks for kidney donors. Kidney Int. 2014;86:162-167.
42. Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. N Engl J Med. 2009;360:459-469.
43. Lentine KL, Schnitzler MA, Xiao H, et al. Racial variation in medical outcomes among living kidney donors. N Engl J Med. 2010;363:724-732.
44. McClellan WM, Flanders WD. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol. 2003;14(7 suppl 2):S65-S70.
45. Young BA, Katz R, Boulware LE, et al. Risk factors for rapid kidney function decline among African Americans: The Jackson Heart Study (JHS). Am J Kidney Dis. 2016;68:229-239.
46. Tin A, Grams ME, Estrella M, et al. Patterns of kidney function decline associated with APOL1 genotypes: results from AASK. Clin J Am Soc Nephrol. 2016;11:1353-1359.
47. Parsa A, Kao WH, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369:2183-2196.
48. Cherikh WS, Young CJ, Kramer BF, et al. Ethnic and gender related differences in the risk of end-stage renal disease after living kidney donation. Am J Transplant. 2011;11:1650-1655.
49. Lentine KL, Schnitzler MA, Garg AX, et al. Race, relationship and renal diagnoses after living kidney donation. Transplantation. 2015;99:1723-1729.
50. Gibney EM, King AL, Maluf DG, et al. Living kidney donors requiring transplantation: focus on African Americans. Transplantation. 2007;84:647-649.